Biotechnology Letters 2010-01-01

Diastereoselective synthesis of L: -threo-3,4-dihydroxyphenylserine by low-specific L: -threonine aldolase mutants.

Hui-Jeong Gwon, Sang-Ho Baik

Index: Biotechnol. Lett. 32(1) , 143-9, (2010)

Full Text: HTML

Abstract

Diastereoselectivity-enhanced mutants of L: -threonine aldolase (L: -TA) for L: -threo-3,4-dihydroxyphenylserine (L: -threo-DOPS) synthesis were isolated by error-prone PCR followed by a high-throughput screening. The most improved mutant was achieved from the mutant T3-3mm2, showing a 4-fold increase over the wild-type L: -TA. When aldol condensation activity was examined using whole cells of T3-3mm2, its de was constantly maintained at 55% during the batch reactions for 80 h, yielding 3.8 mg L: -threo-DOPS/ml.

Related Compounds

  • droxidopa

Related Articles:

Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations.

2014-11-20

[Eur. J. Pharm. Sci. 64 , 37-43, (2014)]

[Acute poisoning of droxidopa: report of a case].

2013-09-01

[Chudoku. Kenkyu. 26(3) , 244-5, (2013)]

The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.

2012-01-01

[Neurobiol. Aging 33(8) , 1651-63, (2012)]

Comment on "Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension" by Fujisaki et al.

2007-10-01

[Ther. Apher. Dial. 11(5) , 407-8, (2007)]

Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.

2015-01-01

[Hypertension 65(1) , 101-7, (2015)]

More Articles...